NATHAN SANBORN: Open Payments
NPI 1235861022 · SALEM, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,235 in 85 payments from 20 companies in 2025. Trend: 2023 $1,149 · 2024 $1,285 · 2025 $1,235
Food & beverage: $1,235
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $241 |
| Astellas Pharma US Inc | 9 | $182 |
| AstraZeneca Pharmaceuticals LP | 6 | $160 |
| Aimmune Therapeutics, Inc. | 15 | $142 |
| Otsuka America Pharmaceutical, Inc. | 5 | $75 |
| Novartis Pharmaceuticals Corporation | 3 | $66 |
| Axsome Therapeutics, Inc. | 4 | $58 |
| Amgen Inc. | 3 | $48 |
| Neurocrine BioSciences, Inc. | 2 | $42 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $34 |
Products named: Veozah, VRAYLAR, ZENPEP, FARXIGA, REXULTI, LEQVIO, EVENITY, UBRELVY.
Industry payments across UT — which companies pay providers there.
